Radcliffe & CardioNerds @AHA22: PROGRESSIVE-AF: Impact of “First-Line” Rhythm Therapy on Afib Progression

Published: 15 Nov 2022

  • Views:

    Views Icon 632
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

AHA 22 - Dr Kate Wilcox, CardioNerds Academic Fellow (Medical College of Wisconsin, US) joins us in this collaboration between the @CardioNerds and Radcliffe Cardiology to interview Dr Jason Andrade (Vancouver General/Montreal Heart Institute, CA), investigator of the late-breaking PROGRESSIVE-AF trial (NCT05514860).

The aim of PROGRESSIVE-AF is to assess if the initial treatment choice, cryoballoon-based PVI or anti-arrhythmic drug therapy influences AF disease progression, as measured by continuous cardiac monitoring.

The trial showed that first-line ablation was associated with a significantly lower progression to persistent atrial fibrillation when compared to initial anti-arrhythmic drug therapy.

Access our full AHA 22 Scientific Coverage here.  

Recorded remotely from Montreal and Wisconsin. 

Editor: Mirjam Boros
Video Specialist: Oliver Miles